Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Free full text

Full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Review

Clinical Trial, Phase I

Research Support, N.I.H., Extramural

Comparative Study

Systematic Review

Clinical Trial, Phase II

Clinical Trial, Phase IV

Clinical Trial

Multicenter Study

Publication Year

From

Quick links

Individual year

2022

2021

2020

2019

2018

2017

2016

2010

2006

2004

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Neurokinin-1 Receptor Antagonists""[mesh_terms]

14 Results

Searching titles within these results

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Alice He, Jihad M Alhariri, Ronald J Sweren, Madan M Kwatra, Shawn G Kwatra

BioMed research international 2018;2017():4790810

Free Full Text

Abstract

Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.

Jesse L Carlin, V Rose Lieberman, Arya Dahal, Madison S Keefe, Changfu Xiao, Gunther Birznieks, Thomas L Abell, Anthony Lembo, Henry P Parkman, Mihael H Polymeropoulos

Gastroenterology 2021;160(1):76-87.e4

Free Full Text

Abstract

The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains.

M Muñoz, M Krämer, R Coveñas

Acta virologica 2019;63(3):253-260

Free Full Text

Abstract

IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Theoharis C Theoharides, Bodi Zhang, Duraisamy Kempuraj, Michael Tagen, Magdalini Vasiadi, Asimenia Angelidou, Konstantinos-Dionysios Alysandratos, Dimitris Kalogeromitros, Shahrzad Asadi, Nikolaos Stavrianeas, Erika Peterson, Susan Leeman, Pio Conti

Proceedings of the National Academy of Sciences of the United States of America 2010;107(9):4448-53

Free Full Text

Abstract

Experimental medication treatment approaches for depression.

D F Ionescu, G I Papakostas

Translational psychiatry 2017;7(3):e1068

Free Full Text

Abstract

Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.

Xiaodong Wang, Jing Wang, Sujata Arora, Lorraine Hughes, Jennifer Christensen, Sharon Lu, Zhi-Yi Zhang

Journal of clinical pharmacology 2020;59(4):488-499

Full Text

Abstract

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.

Brendan M Johnson, Laurel M Adams, Ke Zhang, Shelby D Gainer, Lyndon C Kirby, Robert A Blum, Glen Apseloff, Royce A Morrison, Ralph A Schutz, Peter F Lebowitz

Journal of clinical pharmacology 2010;50(8):951-9

Full Text

Abstract

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.

Mats Bergström, Richard J Hargreaves, H Donald Burns, Michael R Goldberg, David Sciberras, Scott A Reines, Kevin J Petty, Mattias Ogren, Gunnar Antoni, Bengt Långström, Olli Eskola, Mika Scheinin, Olof Solin, Anup K Majumdar, Marvin L Constanzer, Wendy P Battisti, Thomas E Bradstreet, Cynthia Gargano, Jarmo Hietala

Biological psychiatry 2004;55(10):1007-12

Full Text

Abstract

The neuropeptide substance P regulates aldosterone secretion in human adrenals.

Julien Wils, Céline Duparc, Anne-Françoise Cailleux, Antoine-Guy Lopez, Caroline Guiheneuf, Isabelle Boutelet, Hadrien-Gaël Boyer, Christophe Dubessy, Saloua Cherifi, Bruno Cauliez, Françoise Gobet, Guillaume Defortescu, Jean-François Ménard, Estelle Louiset, Hervé Lefebvre

Nature communications 2020;11(1):2673

Free Full Text

Abstract

Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.

Ronald Chow, May Tsao, Leonard Chiu, Marko Popovic, Milica Milakovic, Henry Lam, Carlo DeAngelis

Annals of palliative medicine 2018;7(2):221-233

Free Full Text

Abstract

Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.

Deepti Jacob, Irene Busciglio, Duane Burton, Houssam Halawi, Ibironke Oduyebo, Deborah Rhoten, Michael Ryks, W Scott Harmsen, Michael Camilleri

American journal of physiology. Gastrointestinal and liver physiology 2017;313(5):G505-G510

Free Full Text

Abstract

Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.

Mototsugu Shimokawa, Toshinobu Hayashi, Junichi Nishimura, Taroh Satoh, Mutsumi Fukunaga, Reiko Matsui, Yasushi Tsuji, Fumitaka Mizuki, Takahiro Kogawa

BMC cancer 2022;21(1):1111

Free Full Text

Abstract

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Pablo Tebas, Sergei Spitsin, Jeffrey S Barrett, Florin Tuluc, Okan Elci, James J Korelitz, Wayne Wagner, Angela Winters, Deborah Kim, Renae Catalano, Dwight L Evans, Steven D Douglas

AIDS (London, England) 2016;29(8):931-9

Free Full Text

Abstract

Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells.

Margherita Gallicchio, Arianna Carolina Rosa, Elisa Benetti, Massimo Collino, Chiara Dianzani, Roberto Fantozzi

British journal of pharmacology 2006;147(6):681-9

Free Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Neurokinin-1 Receptor Antagonists""[mesh_terms]

Aprepitant for the Treatment of Chronic Refractory Pruritus.

Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.

The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains.

IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Experimental medication treatment approaches for depression.

Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.

The neuropeptide substance P regulates aldosterone secretion in human adrenals.

Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.

Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.

Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells.

Results for
""Neurokinin-1 Receptor Antagonists""[mesh_terms]